AstraZeneca vs. Apotex: Dapagliflozin/Metformin Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | AstraZeneca AB v. Apotex Inc. |
| Case Number | 1:24-cv-00551 (D. Del.) |
| Court | District of Delaware |
| Duration | May 2024 – July 2025 1 year 2 months |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Apotex’s ANDA submissions for Dapagliflozin/Metformin HCl Extended-Release Tablets (2.5mg/500mg, 2.5mg/1000mg, 5mg/500mg, 5mg/1000mg, 10mg/500mg, 10mg/1000mg) |
Case Overview
The Parties
⚖️ Plaintiff
Global biopharmaceutical company headquartered in Stockholm, Sweden, protecting its diabetes, cardiovascular, and respiratory franchises.
🛡️ Defendant
Large Canadian generic pharmaceutical manufacturer with extensive ANDA filing histories in the U.S. market.
Patents at Issue
This case centered on four U.S. patents asserted by AstraZeneca, forming a layered exclusivity strategy around dapagliflozin-containing combination products:
- • U.S. Patent No. 7,919,598 — Compound and composition claims relating to dapagliflozin
- • U.S. Patent No. 8,501,698 — Formulation or method-of-treatment claims
- • U.S. Patent No. 8,685,934 — Extended-release formulation claims
- • U.S. Patent No. 9,616,028 — Later-generation claims, potentially covering combination therapy
Developing a generic drug?
Check if your pharmaceutical formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The parties filed a stipulated dismissal on July 29, 2025, terminating all claims and counterclaims without prejudice under Fed. R. Civ. P. 41(a)(2). Critically:
- No damages were assessed or disclosed
- No injunctive relief was entered
- Each party bears its own costs and fees
Key Legal Issues
The dismissal without prejudice, particularly after Apotex narrowed its invalidity counterclaims to later-generation formulation patents (8,685,934 and 9,616,028), highlights the strategic dance in ANDA litigation. It suggests a commercially driven resolution potentially involving a licensing agreement or a revision to Apotex’s ANDA scope, allowing both parties to avoid further litigation costs while preserving their legal positions for the future.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims for your drug formulations.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Pharma
This case highlights critical IP risks in pharmaceutical formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all 4 patents and their claim scope
- Analyze validity challenges against specific patents
- Understand the impact of “dismissal without prejudice”
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug or formulation.
- Input your formulation details or API structure
- AI identifies potentially blocking patents in pharma
- Get actionable risk assessment report
High Risk Area
Dapagliflozin/Metformin ER Formulations
4 Asserted Patents
In dapagliflozin combination space
Strategic Dismissal
Preserves options for both parties
✅ Key Takeaways
For Patent Attorneys & Litigators
Dismissal without prejudice preserves all future litigation options for patent holders (unlike a consent judgment of noninfringement).
Search related case law →Targeted invalidity challenges (as Apotex’s amended counterclaims showed) are often more effective than broad-spectrum attacks in complex pharma litigation.
Explore pharma litigation strategies →For R&D Teams
Combination therapy and extended-release formulation patents (e.g., Xigduo XR) can sustain exclusivity long after primary compound patent expiration.
Start FTO analysis for my formulation →Thorough FTO analysis and lifecycle management planning are crucial for generic drug development and branded pharma portfolio protection.
Try AI patent drafting for pharma →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.